µÚÒ»·¶ÎÄÍø - רҵÎÄÕ·¶ÀýÎĵµ×ÊÁÏ·ÖÏíÆ½Ì¨

ÃâÒßѧÃû´Ê½âÊÍ

À´Ô´£ºÓû§·ÖÏí ʱ¼ä£º2025/9/16 12:01:27 ±¾ÎÄÓÉloading ·ÖÏí ÏÂÔØÕâÆªÎĵµÊÖ»ú°æ
˵Ã÷£ºÎÄÕÂÄÚÈݽö¹©Ô¤ÀÀ£¬²¿·ÖÄÚÈÝ¿ÉÄܲ»È«£¬ÐèÒªÍêÕûÎĵµ»òÕßÐèÒª¸´ÖÆÄÚÈÝ£¬ÇëÏÂÔØwordºóʹÓá£ÏÂÔØwordÓÐÎÊÌâÇëÌí¼Ó΢ÐźÅ:xxxxxxx»òQQ£ºxxxxxx ´¦Àí£¨¾¡¿ÉÄܸøÄúÌṩÍêÕûÎĵµ£©£¬¸ÐлÄúµÄÖ§³ÖÓëÁ½⡣

ÃâÒßѧÃû´Ê½âÊÍ

1¡¢ÃâÒߣ¨Immunity£©£ºÃâÒßÊÇÖ¸»úÌåʶ±ðºÍÇå³ýÒ»Çп¹Ô­ÒìÎïÒÔ±£³Ö×ÔÉíÎȶ¨µÄÉúÀí·´Ó¦£¬Èç¹ûÃâÒßϵͳʧµ÷£¬ÃâÒß·´Ó¦¹ýÇ¿¡¢¹ýÈõ»ò¶Ô×ÔÉí³É·Ö·¢ÉúÃâÒßÓ¦´ð¶¼½«¶Ô»úÌåÔì³ÉË𺦡£

2¡¢ÃâÒß·ÀÓù£¨immunologic defense£©£ºÃâÒß·ÀÓùÖ¸·ÀÖ¹Íâ½ç²¡Ô­ÌåÈëÇÖºÍÇå³ýÒÑÈëÇÖ²¡Ô­Ìå¼°ÓꦵÄÉúÎïÐÔ·Ö×Ó£¬´Ë¹¦ÄܾÍÊÇ»úÌåµÄ¿¹¸ÐȾÃâÒß¡£µ«Òì³£Çé¿öÏ£¬ÃâÒß·´Ó¦¹ýÇ¿¿ÉÒýÆð³¬Ãô·´Ó¦£¬¶øÃâÒß¹¦ÄܹýµÍÔò±íÏÖΪÒ×ÊܸÐȾ»òÃâÒßȱÏݲ¡µÈ¡£

3¡¢ÃâÒß×ÔÎÈ£º£¨immune homeostasis£©£ºÃâÒß×ÔÎÈÖ¸»úÌå¶Ô×ÔÉí³É·ÖµÄÄÍÊÜ£¬¶Ô×ÔÉíË¥ÀϺÍËðÉËϸ°ûµÄÇå³ý£¬×èÖ¹ÍâÀ´ÒìÎïÈëÇÖ²¢Í¨¹ýÃâÒßµ÷½Ú´ïµ½Î¬³Ö»úÌåÄÚ»·¾³Îȶ¨µÄ¹¦ÄÜ¡£

4¡¢ÃâÒß¼àÊÓ£¨immunologic surveillance£©£ºÃâÒß¼àÊÓÊÇÖ¸¼à¶½»úÌåÄÚ»·¾³³öÏÖµÄÍ»±äϸ°û¼°ÔçÆÚÖ×Áö£¬²¢ÓèÒÔÇå³ý¡£Èô´Ë¹¦ÄÜʧµ÷£¬ÌåÄÚÍ»±äϸ°ûʧ¿Ø£¬¿Éµ¼ÖÂÖ×Áö·¢Éú£¬Èô²¡¶¾¸ÐȾ²»Äܼ°Ê±±»Çå³ý£¬¶ø³öÏÖ²¡¶¾³ÖÐøÐÔ¸ÐȾ״̬¡£ 5¡¢ÁܰÍϸ°û¹é³²(lymphocyte homing )£º³ÉÊìÁܰÍϸ°ûÀ뿪ÖÐÊàÁÜ°ÍÆ÷¹Ùºó£¬¾­ÑªÒºÑ­»·Ç÷ÏòÐÔÇ¨ÒÆ²¢¶¨¾ÓÔÚÍâÖÜÁÜ°ÍÆ÷¹Ù»ò×éÖ¯µÄÌØ¶¨ÇøÓò£¬³ÆÎªÁܰÍϸ°û¹é³²¡£

6¡¢ÁܰÍϸ°ûÔÙÑ­»·(lymphocyte recirculation)£º¶¨¾ÓÔÚÍâÖÜÁÜ°ÍÆ÷¹ÙµÄÁܰÍϸ°û£¬¿ÉÓÉÊä³öÁܰ͹ܾ­Áܰ͸ɡ¢Ðص¼¹Ü»òÓÒÁܰ͵¼¹Ü½øÈëѪҺѭ»·£¬ÁܰÍϸ°ûËæÑªÒºÑ­»·µ½´ïÍâÖÜÃâÒ߯÷¹Ùºó£¬¿É´©Ô½HEV£¬²¢ÖØÐ·ֲ¼ÓÚÈ«ÉíÁÜ°ÍÆ÷¹ÙºÍ×éÖ¯¡£ÁܰÍϸ°ûÔÚѪҺ¡¢ÁܰÍÒº¡¢ÁÜ°ÍÆ÷¹Ù»ò×éÖ¯¼ä·´¸´Ñ­»·µÄ¹ý³Ì³ÆÎªÁܰÍϸ°ûÔÙÑ­»·¡£

7¡¢¿¹Ô­£¨Antigen£¬Ag£©£ºÊÇÒ»ÀàÄܴ̼¤»úÌåÃâÒßϵͳ²úÉúÌØÒìÐÔÃâÒßÓ¦´ð,²¢ÄÜ

ÓëÏàÓ¦µÄÃâÒßÓ¦´ð²úÎïÔÚÌåÄÚ»òÌåÍâ·¢ÉúÌØÒìÐÔ½áºÏµÄÎïÖÊ¡£

ÃâÒßÔ­ÐÔ(Immunogenicity):ÊÇÖ¸¿¹Ô­Äܴ̼¤Ìض¨µÄÃâÒßϸ°û£¨¿Ë¡£©,ʹ֮»î»¯¡¢ÔöÖ³¡¢·Ö»¯,²úÉúÃâÒßЧӦÎïÖÊ(¿¹ÌåºÍÖÂÃôÁܰÍϸ°û)µÄÌØÐÔ.

ÃâÒß·´Ó¦ÐÔ(Immunoreactivity)£»Ò²³Æ¿¹Ô­ÐÔ(Antigenicity):ÊÇÖ¸¿¹Ô­ÓëÏàÓ¦µÄÃâÒßЧӦÎïÖÊ(¿¹Ìå»ò/ºÍÖÂÃôÁܰÍϸ°û£©,ÔÚÌåÄÚÌåÍâ·¢ÉúÌØÒìÐÔ½áºÏµÄÌØÐÔ. 8¡¢°ë¿¹Ô­£¨hapten£©£º ½öÓÐÃâÒß·´Ó¦ÐÔ¶øÎÞÃâÒßÔ­ÐÔµÄÎïÖÊ¡£Èç:´ó¶àÊý¶àÌÇ¡¢ÀàÖ¬¡¢Ä³Ð©Ò©Îï¡£°ë¿¹Ô­+ÔØÌå(µ°°×ÖÊ)¡úÍêÈ«¿¹Ô­¡£

9¡¢¿¹Ô­¾ö¶¨´Ø£¨antigenic determinant £»epitope)£ºÖ¸¿¹Ô­·Ö×ÓÖоö¶¨¿¹Ô­ÌØÒìÐÔµÄÌØÊ⻯ѧ¹¦ÄÜ»ùÍÅ¡£ËüÊÇTCR/BCR¼°¿¹ÌåÌØÒì½áºÏµÄ»ù±¾µ¥Î»£¬ÓֳƱíλ¡£ÆäÐÔÖÊ¡¢ÊýÄ¿¡¢¿Õ¼ä¹¹Ð;ö¶¨ÁË¿¹Ô­µÄÌØÒìÐÔ¡£

10¡¢¹¹Ïó¾ö¶¨´Ø£¨conformational determinants£©£ºÐòÁÐÉϲ»Á¬ÐøµÄ¶àëÄ»ò¶àÌÇ£¬Óɿռ乹ÏóÐγɵľö¶¨´Ø£¬Äܱ»Bϸ°û»ò¿¹Ìåʶ±ð£¬¿ÉÖ±½ÓÓëBϸ°û±íÃæµÄ¿¹Ô­ÊÜÌå½áºÏ£¬ÎÞÐèAPC¼Ó¹¤µÝ³ÊºÍMHCÀà·Ö×Ó¡£

11¡¢Ë³Ðò¾ö¶¨´Ø(sequential determinant)£»ÏßÐÔ¾ö¶¨´Ø£¨linear determinants£©£ºÒ»¶ÎÐòÁÐÉÏÏàÁ¬ÐøµÄ°±»ùËáÆ¬¶ÎËùÐγɵľö¶¨´Ø£¬Î»ÓÚ·Ö×Ó±íÃæ»ò·Ö×ÓÄÚ²¿£¬Ö÷Òª±»Tϸ°ûʶ±ð£»ÓÐЩҲÄܱ»Bϸ°ûʶ±ð¡£Ðè¾­ÀúAPC¼Ó¹¤µÝ³Ê£¬²¢ÓëMHCÀà·Ö×Ó½áºÏºó£¬²ÅÄܱ»¿¹Ô­ÊÜÌåʶ±ð¡£

12¡¢ÐØÏÙÒÀÀµÐÔ¿¹Ô­£¨thymus dependent Ag £¬TD-Ag£©£º1£©¾ø´ó¶àÊýÊǵ°°×ÖÊ¿¹Ô­£¬ÓÉBϸ°û±í루°ë¿¹Ô­£©¼°Tϸ°û±íλ£¨ÔØÌ壩¹¹³É£»£²£©²úÉúµÄ¿¹ÌåÖ÷ÒªÊÇIgG£»£³£©¿ÉÒýÆðϸ°ûÃâÒß¡¢ÌåÒºÃâÒߣ»£´£©¿É²úÉúÃâÒß¼ÇÒ䣬ÐèTϸ°û¸¨Öú²ÅÄܼ¤»îBϸ°û²úÉúAb¿¹Ô­ÎïÖÊ¡£

13¡¢ÐØÏÙ·ÇÒÀÀµÐÔ¿¹Ô­£¨thymus independent Ag£¬TI-Ag£©£º1£©¾ø´ó¶àÊýΪ¶àÌÇÀàÎïÖÊ£»2£©º¬Óжà¸öÖØ¸´ÅÅÁеÄBϸ°û±íλ£»3£©¿¹ÌåÖ÷ÒªÊÇIgM£»4£©²»ÒýÆðϸ

°ûÃâÒßÓ¦´ð£»5£©²»²úÉúÃâÒß¼ÇÒ䣬ÎÞÐèTϸ°û¸¨Öú±ãÄܲúÉú¿¹Ìå¡£

14¡¢Ö×ÁöÌØÒìÐÔ¿¹Ô­£¨Tumor specific antigens£¬TSA£©£ºÖ»´æÔÚÓÚÖ×Áöϸ°û¶ø²»´æÔÚÓÚÕý³£Ï¸°ûµÄп¹Ô­£¬¼´Ö×Áöϸ°ûËùÌØÓеĿ¹Ô­¡£

15¡¢Ö×ÁöÏà¹ØÐÔ¿¹Ô­£¨Tumor associated antigens£¬TAA£©£º·ÇÖ×Áöϸ°ûËùÌØÓУ¬Õý³£Ï¸°ûÉÏÒ²´æÔÚ£»Ö»ÊÇÕý³£Ï¸°ûÖÐ΢Á¿±í´ï£¬Ï¸°û°©±äʱ£¬Æäº¬Á¿Ã÷ÏÔÔö¸ß¡£ 16¡¢ÒìÊÈÐÔ¿¹Ô­£¨hetreophilic Ag£©£ºÒ»ÀàÓëÖÖÊôÌØÒìÐÔÎ޹أ¬´æÔÚÓÚ²»Í¬ÖÖϵÉúÎï¼äµÄ¹²Í¬¿¹Ô­¡£ÒâÒ壨1£©ÒýÆðijЩ²¡Àí·´Ó¦£¨2£©Ð­ÖúÕï¶ÏijЩ¼²²¡ 17¡¢¹²Í¬¿¹Ô­£¨common antigen£©£º ´æÔÚÓÚÁ½ÖÖ²»Í¬µÄ¿¹Ô­Ö®¼äµÄÏàͬ»òÏàËÆµÄ¿¹Ô­¾ö¶¨´Ø£¬³ÆÎª¹²Í¬¿¹Ô­¡£

18¡¢½»²æ·´Ó¦£¨cross reaction£©£ºÓÉÓÚ´æÔÚ¹²Í¬¿¹Ô­Ôì³É¿¹Ìå¶Ô¾ßÓÐÏàͬ»òÏàËÆ¾ö¶¨´ØµÄ²»Í¬¿¹Ô­·¢Éú·´Ó¦£¬´Ë³ÆÎª½»²æ·´Ó¦¡£

19¡¢³¬¿¹Ô­£¨Superantigens£©£ºÄ³Ð©¿¹Ô­ÎïÖÊÖ»Ð輫µÍŨ¶È£¨1-10ng/ml£©¼´¿É¼¤»î´óÁ¿T»òBϸ°û¿Ë¡£¨5-20%£©£¬²úÉú¼«Ç¿µÄÃâÒßÓ¦´ð£¬ÕâÀ࿹ԭ³ÆÎª³¬¿¹Ô­¡£¿É·ÖΪ£º£Ôϸ°û³¬¿¹Ô­£¬£Âϸ°û³¬¿¹Ô­ºÍTCR¦Ã¦ÄT ³¬¿¹Ô­¡£

20¡¢×ô¼Á£¨Adjuvants£©£ºÖ¸Ó뿹ԭһÆð»òÔ¤ÏÈ×¢Éäµ½»úÌ壬ÄÜÔöÇ¿»úÌå¶Ô¸Ã¿¹Ô­µÄÃâÒßÓ¦´ð»ò¸Ä±äÃâÒßÓ¦´ðÀàÐ͵ÄÎïÖÊ¡£

21¡¢¿¹Ì壨Antibody£©£ºÖ¸BÁܰÍϸ°ûÊÜ¿¹Ô­´Ì¼¤ºó»î»¯¡¢ÔöÖ³¡¢·Ö»¯³ÉΪ½¬Ï¸°û£¬²úÉúµÄÄÜÓëÏàÓ¦¿¹Ô­·¢ÉúÌØÒìÐÔ½áºÏµÄÃâÒßÇòµ°°×¡£´æÔÚÐÎʽ£º Bϸ°ûĤÉϵÄĤÐÍ¿¹Ô­ÊÜÌ壻·ÖÃÚ½øÈëÌåÒº, ½éµ¼ÌåÒºÃâÒßÓ¦´ðµÄ·ÖÃÚÐÍ¿¹Ìå¡£

22¡¢ÃâÒßÇòµ°°×£¨Immunoglobulin£©£ºÖ¸¾ßÓп¹Ìå»îÐÔ»ò»¯Ñ§½á¹¹Ó뿹ÌåÏàËÆµÄÇòµ°°×£¬°üÀ¨£º¾ßÓÐÃâÒß»îÐÔµÄÕý³£¿¹Ì壻ûÓп¹Ìå»îÐÔµÄÒì³£ÃâÒßÇòµ°°×¡£¿¹ÌåÒ»¶¨ÊÇÃâÒßÇòµ°°×£»ÃâÒßÇòµ°°×²»Ò»¶¨¶¼ÊÇ¿¹Ìå¡£

23¡¢¾ö¶¨´Ø»¥²¹Çø£¨complementarity¡ªdetermining region£¬CDR£©£ºVL¡¢VHµÄ³¬

ËÑË÷¸ü¶à¹ØÓÚ£º ÃâÒßѧÃû´Ê½âÊÍ µÄÎĵµ
ÃâÒßѧÃû´Ê½âÊÍ.doc ½«±¾ÎĵÄWordÎĵµÏÂÔØµ½µçÄÔ£¬·½±ã¸´ÖÆ¡¢±à¼­¡¢ÊղغʹòÓ¡
±¾ÎÄÁ´½Ó£ºhttps://www.diyifanwen.net/c1ypkj3e3p65ap1c1kzfj507xn0uyj200qke_1.html£¨×ªÔØÇë×¢Ã÷ÎÄÕÂÀ´Ô´£©
ÈÈÃÅÍÆ¼ö
Copyright © 2012-2023 µÚÒ»·¶ÎÄÍø °æÈ¨ËùÓÐ ÃâÔðÉùÃ÷ | ÁªÏµÎÒÃÇ
ÉùÃ÷ :±¾ÍøÕ¾×ðÖØ²¢±£»¤ÖªÊ¶²úȨ£¬¸ù¾Ý¡¶ÐÅÏ¢ÍøÂç´«²¥È¨±£»¤ÌõÀý¡·£¬Èç¹ûÎÒÃÇ×ªÔØµÄ×÷Æ·ÇÖ·¸ÁËÄúµÄȨÀû,ÇëÔÚÒ»¸öÔÂÄÚ֪ͨÎÒÃÇ£¬ÎÒÃǻἰʱɾ³ý¡£
¿Í·þQQ£ºxxxxxx ÓÊÏ䣺xxxxxx@qq.com
ÓåICP±¸2023013149ºÅ
Top